Publications

Detailed Information

T-Cell-Derived Nanovesicles for Cancer Immunotherapy

Cited 43 time in Web of Science Cited 43 time in Scopus
Authors

Hong, Jihye; Kang, Mikyung; Jung, Mungyo; Lee, Yun Young; Cho, Yongbum; Kim, Cheesue; Song, Seuk Young; Park, Chun Gwon; Doh, JunsangKim, Byung-Soo

Issue Date
2021-08
Publisher
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Citation
Advanced Materials, Vol.33 No.33, p. 2101110
Abstract
Although T-cell therapy is a remarkable breakthrough in cancer immunotherapy, the therapeutic efficacy is limited for solid tumors. A major cause of the low efficacy is T-cell exhaustion by immunosuppressive mechanisms of solid tumors, which are mainly mediated by programmed death-ligand 1 (PD-L1) and transforming growth factor-beta (TGF-beta). Herein, T-cell-derived nanovesicles (TCNVs) produced by the serial extrusion of cytotoxic T cells through membranes with micro-/nanosized pores that inhibit T-cell exhaustion and exhibit antitumoral activity maintained in the immunosuppressive tumor microenvironment (TME) are presented. TCNVs, which have programmed cell death protein 1 and TGF-beta receptor on their surface, block PD-L1 on cancer cells and scavenge TGF-beta in the immunosuppressive TME, thereby preventing cytotoxic-T-cell exhaustion. In addition, TCNVs directly kill cancer cells via granzyme B delivery. TCNVs successfully suppress tumor growth in syngeneic-solid-tumor-bearing mice. Taken together, TCNV offers an effective cancer immunotherapy strategy to overcome the tumor's immunosuppressive mechanisms.
ISSN
0935-9648
URI
https://hdl.handle.net/10371/202453
DOI
https://doi.org/10.1002/adma.202101110
Files in This Item:
There are no files associated with this item.
Appears in Collections:

Related Researcher

  • College of Engineering
  • Department of Materials Science & Engineering
Research Area Ex Vivo Models, Lymphocyte Biology, Smart Biomaterials

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share